DrugPatentWatch Database Preview
Patent: 8,507,505
» See Plans and Pricing
Summary for Patent: 8,507,505
| Title: | Dihydropyrazolopyrimidinone derivative |
| Abstract: | The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar.sup.1 is an optionally substituted aryl or heteroaryl group; R.sup.1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R.sup.2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R.sup.3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy. ##STR00001## |
| Inventor(s): | Bamba; Makoto (Ibaraki, JP), Furuyama; Hidetomo (Kanagawa, JP), Sakamoto; Toshihiro (Ibaraki, JP), Sunami; Satoshi (Ibaraki, JP), Takahashi; Keiji (Chiba, JP), Yamamoto; Fuyuki (Ibaraki, JP), Yoshizumi; Takashi (Ibaraki, JP) |
| Assignee: | MSD K.K. (Chiyoda-Ku, Tokyo, JP) |
| Application Number: | 13/133,673 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,507,505
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | Orphan | search |
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 010 | 2001-09-17 | Start Trial | MSD K.K. (Chiyoda-Ku, Tokyo, JP) | 2028-12-12 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,507,505
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010067886 | Start Trial |
| United States of America | 2011243891 | Start Trial |
| Japan | 2012511502 | Start Trial |
| European Patent Office | 2376493 | Start Trial |
| Canada | 2745970 | Start Trial |
| Australia | 2009325398 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
